Annual report pursuant to Section 13 and 15(d)

INCOME TAXES (Tables)

v3.24.3
INCOME TAXES (Tables)
12 Months Ended
Dec. 31, 2023
Income Tax Disclosure [Abstract]  
Schedule of provision for income taxes
               
   

Year Ended

December 31,

 
    2023     2022  
Current tax provision:                
Federal   $ -     $ -  
State     -       -  
Foreign     (496 )     (197 )
Total current     (496 )     (197 )
                 
Deferred tax provision:                
Federal     -       -  
State     -       -  
Total deferred     -       -  
Total income tax benefit   $ (496 )   $ (197 )
Schedule of income tax benefit
         
Country   NOL
Carryforwards
  Expiry Terms
U.K.   $ 298,723   Does not expire
U.S.     53,872   Expires in up to 15 years
U.S.     9,926   Does not expire
Australia     5,252   Does not expire
Israel     372,927   Does not expire
Finland     93   Expires in up to 6 years
Other     1,736   Expires in up to 4 years
Schedule of deferred tax assets
               
    As of
December 31,
 
    2023     2022  
Net operating loss carryforwards   $ 170,256     $ 180,491  
Fixed assets     1,708       2,714  
R&D amortization     6,255       7,928  
Accruals and reserves     21,206       17,585  
R&D and other credits     279       4,493  
Share-based compensation     4,670       8,143  
Total deferred tax assets     204,374       221,354  
Intangible assets     (13 )     (1,049 )
Total deferred tax liabilities     (13 )     (1,049 )
Valuation allowance     (204,361 )     (220,305 )
Total deferred tax assets, net   $ -     $ -  
Schedule of reconciliation of income taxes
               
    Years Ended
December 31,
 
    2023     2022  
Expected income tax benefit at U.S. rates   $ 16,670     $ 17,971  
Difference between U.S. rate and rates applicable to subsidiaries in other jurisdictions     2,281       315  
Expenditures not deductible for tax purposes     (13,645 )     (118 )
Non-deductible officer compensation     (24 )     -  
Tax rate changes outside the U.S.     (1 )     17,594  
Fair market value changes     8,379       1,701  
Expiry of foreign taxable losses     (977 )     1,643  
Other     672       744  
Valuation allowance on tax benefits     15,943       (40,869 )
UK R&D tax credits     582       1,216  
Deferred adjustments due to Mimosa sale     (29,384 )     -  
Income tax benefit   $ 496     $ 197